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A B S T R A C T
Purpose: Caﬀeine is a non-selective antagonist of A1 and A2A adenosine receptors (ARs). In this regard, nitric
oxide (NO) is partly involved in the central eﬀects of caﬀeine. In this study, we examined the eﬀect of acute
caﬀeine administration on pentylenetetrazole (PTZ)-induced seizure threshold by focusing on A1Rs, A2ARs, and
NO-cGMP signaling pathway.
Methods: NMRI male mice (25–30 g) received caﬀeine (5, 50, and 100mg/kg) alone, whereas 8-CPT (1 and
5mg/kg, a selective A1Rs antagonist), SCH-442416 (5 and 10mg/kg, a selective A2ARs antagonist) or sildenaﬁl
(5 and 10mg/kg, a phosphodiesterase 5 inhibitor) were administrated alone or as pre-treatment before caﬀeine.
Seizure threshold was assessed by intravenous infusion of PTZ. Nitric oxide metabolites (NOx) were measured
with the Griess method.
Results: When administrated alone, caﬀeine (5 and 50mg/kg) and 8-CPT (1 and 5mg/kg) signiﬁcantly de-
creased seizure threshold, while 100mg/kg of caﬀeine, SCH-442416 or sildenaﬁl did not change it. Only pre-
treatment with SCH-442416 (5 and 10mg/kg) or sildenaﬁl (5 and 10mg/kg) before 100mg/kg of caﬀeine
signiﬁcantly decreased seizure threshold. Moreover, NOx levels signiﬁcantly decreased following alone ad-
ministration of caﬀeine (100mg/kg) or 8-CPT (5mg/kg).
Conclusion: The results of present study showed that 5 and 50mg/kg of caﬀeine had a proconvulsant eﬀect but
caﬀeine at a dose of 100mg/kg had no eﬀect on seizure threshold. In addition, it seems that the eﬀect caﬀeine on
seizure threshold is partly mediated through ARs or modulation of the NO-cGMP signaling pathway.
1. Introduction
Caﬀeine (1,3,7-trimethylxanthine) belongs to the family of purine
alkaloids and is the main active component of energy drinks and caf-
feine-containing beverages such as tea and coﬀee (Nieber, 2017). Caf-
feine is the non-selective antagonist of adenosine receptors (ARs).
Adenosine as a potent inhibitory neuromodulator has four G protein-
coupled receptors: A1, A2A, A2B, and A3 (El Yacoubi et al., 2001). A1Rs
and A2ARs are the preferential targets of caﬀeine. However, aﬃnities of
caﬀeine and other methylxanthines to A1Rs and A2ARs (with Ki values
of 29 and 48 μM, respectively) are nearly equal (Tchekalarova et al.,
2009).
Some human reports (Bonilha and Li, 2004; Kaufman and Sachdeo,
2003) and animal studies (Cutrufo et al., 1992; Loscher, 2009) show
that caﬀeine is a proconvulsant agent, but its potential pro-epileptic
eﬀect is still a matter of debate. Caﬀeine may induce seizures in rodents
when consumed in high doses (over 400mg/kg) (Chroscinska-
Krawczyk et al., 2011). Caﬀeine has shown a mitigatory eﬀect on sei-
zure threshold in some animal models of epilepsy (Chu, 1981; De Sarro
et al., 1997). Moreover, based on the results of a systematic review
caﬀeine increases seizure susceptibility (van Koert et al., 2018). How-
ever, there are some reports that caﬀeine at doses far less than its
convulsive dose has no signiﬁcant eﬀect on seizure threshold
(Bankstahl et al., 2012; Jargiello-Baszak et al., 2016). Besides, there are
additional reports regarding no eﬀect of caﬀeine against seizures fol-
lowing chronic administration (Germe et al., 2015; El Yacoubi et al.,
2008). These paradoxical eﬀects of caﬀeine may be partly related to its
eﬀects on ARs. It is well established that activation of A1Rs leads to
anticonvulsant eﬀect and proconvulsant eﬀect of caﬀeine to somewhat
is mediated by antagonizing of A1Rs (Boison, 2011). On the other hand,
A2AR is a stimulatory receptor and its activation may aggravate seizures
(El Yacoubi et al., 2008). Thus, it is possible that the paradoxical eﬀect
of caﬀeine on seizures to be partly due to its dose-dependent eﬀect on
A1Rs or A2ARs.
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Nitric oxide (NO), a known neurotransmitter/neuromodulator in
the brain, is involved in many physiological and pathological processes.
NO is generated from L-arginine by various isoforms of nitric oxide
synthase (NOS), namely neuronal NOS, inducible NOS, and endothelial
NOS (Akula et al., 2008). Activation of soluble guanylate cyclase (sGC)
by NO leads to elevation of intracellular second messenger cyclic gua-
nosine monophosphate (cGMP) levels. Levels of cGMP are regulated by
cyclic nucleotide phosphodiesterases (PDEs), which catalyze the hy-
drolysis of cyclic adenosine monophosphate (cAMP) and cGMP (Kaster
et al., 2005). It has been suggested that NO exerts both proconvulsant
(Royes et al., 2005; Riazi et al., 2006) or anticonvulsant eﬀects
(Yahyavi-Firouz-Abadi et al., 2006) depending on the route of admin-
istration and model of seizure. In addition, the results of several studies
demonstrate the modulatory role of the NO-cGMP pathway on the an-
ticonvulsant eﬀect of adenosine (Akula et al., 2008; Kaku et al., 2001).
There is obvious evidence that caﬀeine can modulate NO production
(Lopez-Munoz et al., 1996; Kayir and Uzbay, 2004). For example, NO
production decreases as the result of A1Rs activation, whereas activa-
tion of A2ARs leads to elevation of NO generation (Bruce et al., 2002).
On the other hand, the non-selective NOS inhibitor, Nω-Nitro-L-arginine
methyl ester (L-NAME) potentiates the anticonvulsant eﬀect of adeno-
sine, while either L-arginine or sodium nitroprusside attenuate the an-
ticonvulsant eﬀect of adenosine (Akula et al., 2008). These results show
that the NO-cGMP pathway is probably involved in the central eﬀects of
adenosine.
Overall, it seems that the mechanism of actions of caﬀeine is not
solely by antagonizing of ARs and probably other signaling pathways
such as the NO-cGMP pathway may be involved. Hence, the aim of the
current study is to investigate the eﬀects of acute administration of
caﬀeine on PTZ-induced clonic seizure threshold in mice. Moreover, the
involvement of A1Rs and A2ARs is investigated using selective antago-
nists of these receptors. Finally, the involvement of the NO-cGMP
pathway is evaluated using sildenaﬁl as selective PDE5 inhibitor and
measurement of NO metabolites.
2. Materials and methods
2.1. Animals
A total of 126 male mice of the NMRI strain, bred in the animal
house of Physiology Research Center, Kashan University of Medical
Sciences (age 5–6 weeks and weight 25–30 gr) were used. Animals were
housed (seven animals per cage) in standard polypropylene cages, at a
constant temperature of 22 ± 2℃ and humidity of 50–55%, with au-
tomatically controlled 12/12 h light/dark cycles. All animals were fed a
regular mice chow and water ad libitum. All experiments were per-
formed in accordance with the guide for the Care and Use of Laboratory
Animals (National Institutes of Health Publication No. 85-23, revised
1985) and were approved by the Research and Ethics Committee of
Kashan University of Medical Sciences (ethics code: I.R
KAUMS.MEDNT.REC.1396.18), Kashan, Iran.
2.2. Drugs
Chemicals and drugs used in this study were: PTZ, caﬀeine, 8-CPT (a
selective A1Rs antagonist), SCH-442416 (a selective A2ARs antagonist),
and sildenaﬁl (a PDE5 inhibitor). PTZ was purchased from Sigma (USA)
and all of the other drugs were supplied from Tocris (UK). PTZ (0.5%
solution) was prepared in heparinized sterile saline 0.9% and ad-
ministered as intravenous (i.v.) infusion. Caﬀeine was dissolved in
normal saline solution at desired doses. Sildenaﬁl, 8-CPT, and SCH-
442416 were dissolved in dimethyl sulfoxide (DMSO) according to re-
commended protocol of the manufacturer. All the mentioned drugs
were injected intraperitoneally (i.p.) in a volume of 5ml/kg of body
weight. Drug doses used in this study were based on the results of
previous studies (Faingold et al., 2016; Germe et al., 2015; Riazi et al.,
2006) and pilot experiments.
2.3. Experiments
The animals were randomly divided into 18 groups. Each experi-
mental group consisted of 7 mice based on pilot experiments and pre-
vious study on this seizure model (Heydari and Davoudi, 2017).
In experiment 1(including 4 groups), animals received a i.p. injec-
tion of diﬀerent doses of caﬀeine (5, 50, and 100mg/kg) 30min before
the determination of PTZ- induced clonic seizure threshold. Control
animals received the same volume of saline. Based on this experiment, a
dose of 100mg/kg of caﬀeine was used in subsequent experiments.
In experiment 2 (including 7 groups), mice were acutely admini-
strated with DMSO as control or diﬀerent doses of 8-CPT (1 and 5mg/
kg, i.p), SCH-442416 (5 and 10mg/kg, i.p) or sildenaﬁl (5 and 10mg/
kg, i.p) 30min before determination of PTZ-induced clonic seizure
threshold.
In experiments 3 (including 7 groups), we examined the eﬀect of
pre-treatment with the same doses of 8-CPT (1 and 5mg/kg, i.p), SCH-
442416 (5 and 10mg/kg, i.p) or sildenaﬁl (5 and 10mg/kg, i.p) 30min
before the selected dose of caﬀeine. Control animals received DMSO
before the selected dose of caﬀeine. In all pre-treatment groups, PTZ-
induced clonic seizure was determined 30min after caﬀeine adminis-
tration.
2.4. Seizure induction
PTZ was dissolved in heparinized sterile saline (0.9%) to prepare a
fresh solution with a dose of 5mg/ml before i.v. infusion. The dose and
infusion rate of administered PTZ was 5mg/ml in saline and 0.5ml/
min, respectively. Before testing, each mouse was weighed and placed
in a clear acrylic plastic restrainer, followed by immersing its tail in a
warm water bath (40–45℃) for 1min to dilate the tail veins. Lateral tail
vein of the mouse was catheterized with a 30 dental carpule attached to
a length of No.10 polyethylene (PE) tubing, which was secured to the
tail by a narrow piece of adhesive tape. The PE tubing (approximately
50 cm in length) was attached to a 10ml plastic syringe containing the
PTZ solution (5mg/ml PTZ in 0.9% heparinized saline) mounted into a
syringe pump (Top, Japan). The PTZ solution was subsequently infused
into the tail vein of freely moving mouse at a constant rate of 0.5ml/
min. Times (in seconds) from the start of the infusion to the appearance
of general clonus (forelimb clonus followed by full clonus of the body)
was recorded for each mouse. The recorded times were then converted
to mg/kg PTZ for each mouse depend on PTZ dose administered and
time-related (Heydari and Davoudi, 2017; Mesdaghinia et al., 2010).
2.5. Measurement of NOx
After induction of PTZ-induced seizure, the animals were sacriﬁced
and their brains were removed to determine NOx. The Griess reaction
was used to assay NOx as previously described (Heydari and Davoudi,
2017). First, standard curves for nitrite were prepared. Brain tissue was
homogenized in Tris HCl 50M containing 0.1mM EDTA. Afterward,
100 μl of tissue suspensions were added to the Griess reagent including
100 μl of vanadium (III) chloride (VCl3), 50 μl of sulfanilamide, and
50 μl of N-(1-Naphthyl) ethylenediamine dihydrochloride (NEDD).
VCl3 was used to reduce nitrate to nitrite. The proteins were subse-
quently precipitated by the addition of 50 μl of 10% trichloroacetic
acid. The contents were incubated for 45min and then centrifuged.
Next, supernatants were transferred to a 96-well ﬂat-bottomed micro-
plate. Absorbance was read at 540 nm using microplate reader and ﬁnal
values were calculated from nitrite standard curves. NOx levels were
measured in all groups except sildenaﬁl receiving groups because sil-
denaﬁl is a phosphodiesterase 5 inhibitor.
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2.6. Statistical analysis
Experimental factors were caﬀeine (5, 50, and 100mg/kg), 8-CPT
(1 and 5mg/kg), SCH-442416 (5 and 10mg/kg) and sildenaﬁl (5 and
10mg/kg). All data were expressed as mean ± standard deviation
(SD). Signiﬁcance of diﬀerences in seizure threshold and NOx levels
was done by one-way analysis of variance (ANOVA) followed by
Tukey’s test for multiple comparisons. Signiﬁcance of diﬀerence be-
tween two groups with the same dose of 8-CPT, SCH-442416 or silde-
naﬁl in the absence or presence of caﬀeine was calculated by a two-
tailed Student’s t-test. Diﬀerences were considered statistically sig-
niﬁcant if P < 0.05. The SPSS version 23.0 software was used for all
analyses.
3. Results
3.1. Eﬀect of diﬀerent doses of caﬀeine on PTZ-induced seizure threshold
Fig. 1 illustrates the eﬀect of acute administration of caﬀeine at
diﬀerent doses (5, 50, and 100mg/kg, i.p.) on PTZ-induced clonic
seizure threshold. One-way ANOVA revealed a signiﬁcant eﬀect
(F3,24= 6.98, P=0.002). Post hoc analysis showed that compared to
saline-treated control group (41.25 ± 3.72mg/kg), caﬀeine at doses of
5 and 50mg/kg had a signiﬁcant proconvulsant eﬀect [32.19 ± 4.35
(p=0.004) and 33.14 ± 5.2mg/kg (p=0.011) respectively). In
comparison, caﬀeine at dose of 100mg/kg did not signiﬁcantly change
the seizure threshold [39.06 ± 4.34mg/kg, (p= 0.79)]. Pro-
convulsant eﬀect of caﬀeine and its underlying mechanisms have been
previously described in detail. Our results conﬁrmed and extended the
previous report (Chroscinska-Krawczyk et al., 2011) that caﬀeine at
doses far below its convulsive potential (400mg/kg) did not change the
seizure threshold. Thus, a dose of 100mg/kg of caﬀeine was selected
for further experiments to investigate the possible role of A1Rs and
A2ARs and also NO-cGMP signaling pathway.
3.2. Eﬀect of 8-CPT, a selective antagonist of A1Rs, alone and as pre-
treatment before 100 mg/kg of caﬀeine on PTZ-induced seizure threshold
Fig. 2 shows the eﬀect of acute administration of 8-CPT (1 and
5mg/kg, i.p.) alone or as pre-treatment before 100mg/kg of caﬀeine on
PTZ-induced clonic seizure threshold. When 8-CPT was administrated
alone, one-way ANOVA revealed a signiﬁcant eﬀect (F2,18= 24.31,
P= 0.000). Post hoc analysis showed that compared to DMSO-treated
control group (45.64 ± 5.54mg/kg), 8-CPT at doses of 1 and 5mg/kg
signiﬁcantly decreased PTZ-induced seizure threshold
[35.63 ± 5.11mg/kg (p=0.002) and 28.77 ± 2.31mg/kg
(p= 0.000), respectively].
In pre-treatment groups, the same doses of 8-CPT (1 and 5mg/kg,
i.p.) were acutely administrated 30min before 100mg/kg of caﬀeine
(F2,18= 2.71, P= 0.094). Compared to DMSO+Caﬀeine (100mg/kg)
control group (44.85 ± 6.56mg/kg), pre-treatment with 8-CPT at
doses of 1 and 5mg/kg did not signiﬁcantly change PTZ-induced sei-
zure threshold [43.9 ± 8.73mg/kg (p= 0.971) and
52.58 ± 7.51mg/kg (p=0.170), respectively]. Pre-treatment of
5mg/kg of 8-CPT before 100mg/kg caﬀeine resulted in a signiﬁcant
(p= 0.000) increase in seizure threshold compared to 5mg/kg of 8-
CPT alone group. These results show that despite pre-treatment with 8-
CPT and its antagonizing eﬀect on A1Rs, administration of caﬀeine at a
dose of 100mg/kg had no proconvulsant eﬀect.
3.3. Eﬀect of SCH-442416, a selective antagonist of A2ARs, alone and as
pre-treatment before 100mg/kg of caﬀeine on PTZ-induced seizure
threshold
Fig. 3 shows the eﬀect of acute administration of SCH-442416 (5
and 10mg/kg) alone or as pre-treatment before 100mg/kg of caﬀeine
on PTZ-induced clonic seizure threshold. When SCH-442416 was ad-
ministrated alone, one-way ANOVA did not reveal a signiﬁcant eﬀect
(F2,18= 3.35, P=0.058). Post hoc analysis showed that compared to
DMSO-treated control group (45.64 ± 5.54mg/kg), SCH-442416 at
doses of 5 and 10mg/kg did not signiﬁcantly change PTZ-induced
seizure threshold [40.45 ± 5.88mg/kg (p= 0.21) and
38.19 ± 5.11mg/kg (p=0.053), respectively].
When the same doses of SCH-442416 pre-treated before 100mg/kg
of caﬀeine, one-way ANOVA revealed a signiﬁcant eﬀect
(F2,18= 40.55, P=0.000). Post hoc analysis showed that compared to
DMSO+Caﬀeine (100mg/kg) control group (44.85 ± 6.54mg/kg),
pre-treatment with SCH-442416 at doses of 5 and 10mg/kg sig-
niﬁcantly decreased PTZ-induced seizure threshold [29.62 ± 3.02mg/
kg (p=0.000) and 24.58 ± 2.39mg/kg (p=0.000),
respectively].Meanwhile, pre-treatment of 5 and 10mg/kg of SCH-
442416 before 100mg/kg caﬀeine resulted in a signiﬁcant decrease in
Fig. 1. Eﬀect of diﬀerent doses of caﬀeine (5, 50, and 100mg/kg, i.p.) on the PTZ-induced clonic seizure threshold; *P < 0.05 and **P < 0.01 in comparison with
saline-treated control group (mean ± SD, n= 7).
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the seizure threshold compared to 5 and 10mg/kg of SCH-442416
alone groups (p= 0.001 and p= 0.000 respectively).
3.4. Eﬀect of pre-treatment with sildenaﬁl, a selective inhibitor of PDE5,
alone and as pre-treatment before 100mg/kg of caﬀeine on PTZ-induced
seizure threshold
Fig. 4 shows the eﬀect of acute administration of sildenaﬁl (5 and
10mg/kg) alone or as pre-treatment before 100mg/kg of caﬀeine on
PTZ-induced clonic seizure threshold. When sildenaﬁl was admini-
strated alone, one-way ANOVA did not reveal a signiﬁcant eﬀect
(F2,18= 2.25, P=0.134). Post hoc analysis showed that compared to
DMSO-treated control group (45.64 ± 5.54mg/kg), sildenaﬁl at doses
of 5 and 10mg/kg did not signiﬁcantly change PTZ-induced seizure
threshold [42.06 ± 4.98mg/kg (p=0.36) and 40.28 ± 3.73mg/kg
(p=0.12), respectively].
When the same doses of sildenaﬁl pre-treated before 100mg/kg of
caﬀeine, one-way ANOVA revealed a signiﬁcant eﬀect (F2,18= 34.21,
P= 0.000). Post hoc analysis showed that compared to
DMSO+Caﬀeine (100mg/kg) control group (44.85 ± 6.54mg/kg),
pre-treatment with sildenaﬁl at doses of 5 and 10mg/kg signiﬁcantly
decreased PTZ-induced seizure threshold [32.86 ± 1.5mg/kg
(p= 0.000) and 27.32 ± 2.04mg/kg (p= 0.000), respectively]. Also,
pre-treatment of 5 and 10mg/kg of sildenaﬁl before 100mg/kg caf-
feine resulted in a signiﬁcant decrease in seizure threshold compared to
5 and 10mg/kg of sildenaﬁl alone groups (p=0.001 and p= 0.000
respectively).
3.5. Eﬀect of diﬀerent doses of caﬀeine on NOx levels in the brain
Fig. 5 illustrates the eﬀect of acute administration of caﬀeine at
diﬀerent doses (5, 50, and 100mg/kg, i.p.) on NOx levels in the brain.
One-way ANOVA revealed a signiﬁcant eﬀect (F3,24= 3.11,
P= 0.045). Post hoc analysis showed that compared to saline-treated
control group (69.85 ± 9.48 μM/g tissue), caﬀeine 100mg/kg sig-
niﬁcantly decreased the NOx levels [58.73 ± 5.37 μM/g tissue
Fig. 2. Eﬀect of diﬀerent doses of 8-CPT (1 and 5mg/kg,
i.p.) alone and as pre-treatment before 100mg/kg of caf-
feine on the PTZ-induced clonic seizure threshold;
**P < 0.01 and ***P < 0.001 in comparison with
DMSO-treated control group, +++P < 0.001 in com-
parison with 5mg/kg of 8-CPT alone group (mean ± SD,
n= 7).
Fig. 3. Eﬀect of diﬀerent doses of SCH-442416 (5 and
10mg/kg, i.p.) alone and as pre-treatment before 100mg/
kg of caﬀeine on the PTZ-induced clonic seizure threshold;
***P < 0.001 in comparison with DMSO+Caﬀeine
group, +++P < 0.001 in comparison with 5mg/kg of
SCH-442416 alone group, ###P < 0.001 in comparison
with 10mg/kg of SCH-442416 alone group (mean ± SD,
n= 7).
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(p= 0.035)]. In comparison, caﬀeine at doses of 5 and 50mg/kg did
not signiﬁcantly change NOx levels [63.99 ± 4.07 μM/g (p=0.43)
and 66.91 ± 8.2 μM/g tissue (p= 0.86) respectively].
3.6. Eﬀect of 8-CPT, a selective antagonist of A1Rs, alone and as pre-
treatment before 100 mg/kg of caﬀeine on NOx levels in the brain
Fig. 6 shows the eﬀect of acute administration of 8-CPT (1 and
5mg/kg, i.p.) alone or as pre-treatment before 100mg/kg of caﬀeine on
NOx levels in the brain. When 8-CPT was administrated alone, one-way
ANOVA did not reveal a signiﬁcant eﬀect (F2,18= 1.48, P= 0.254).
Compared to DMSO-treated control group (55.85 ± 11.71 μM/g
tissue), 8-CPT at doses of 1 and 5mg/kg did not signiﬁcantly change
NOx levels [59.54 ± 8.23 μM/g tissue (p=0.79) and 65.57 ± 11.7
μM/g tissue (p=0.23), respectively].
When the same doses of 8-CPT pre-treated before 100mg/kg of
caﬀeine, one-way ANOVA revealed a signiﬁcant eﬀect (F2,18= 6.13,
P=0.009). Post hoc analysis showed that compared to
DMSO+Caﬀeine (100mg/kg) control group (58.69 ± 7.34 μM/g
tissue), 8-CPT at a dose of 5mg/kg signiﬁcantly decreased NOx levels
[48.06 ± 5.82 μM/g tissue (p= 0.007)]. Compared to
DMSO+Caﬀeine (100mg/kg) control group, 8-CPT at a dose of 1mg/
kg did not signiﬁcantly change NOx levels [53.06 ± 3.02 μM/g tissue,
(p= 0.181)]. Meanwhile, pre-treatment of 5mg/kg of 8-CPT before
100mg/kg caﬀeine resulted in a signiﬁcant decrease in NOx levels
compared to 5mg/kg of 8-CPT alone group (p=0.004).
3.7. Eﬀect of SCH-442416, a selective antagonist of A2ARs, alone and as
pre-treatment before 100mg/kg of caﬀeine on NOx levels in the brain
Fig. 7 shows the eﬀect of acute administration of SCH-442416 (5
and 10mg/kg, i.p.) alone or as pre-treatment before 100mg/kg of
caﬀeine on NOx levels in the brain. When SCH-442416 was admini-
strated alone, one-way ANOVA did not reveal a signiﬁcant eﬀect
(F2,18= 0.465, P=0.636). Compared to DMSO-treated control group
(55.85 ± 11.71 μM/g tissue), SCH-442416 at doses of 5 and 10mg/kg
did not signiﬁcantly change NOx levels [53.68 ± 9.98 μM/g tissue
(P= 0.91) and 50.78 ± 7.41 μM/g tissue (P= 0.61), respectively].
When the same doses of SCH-442416 pre-treated before 100mg/kg
of caﬀeine, one-way ANOVA did not reveal a signiﬁcant eﬀect
(F2,18= 1.33, P= 0.29). Post hoc analysis showed that compared to
DMSO+Caﬀeine (100mg/kg) control group (58.69 ± 7.34 μM/g
tissue), SCH-442416 at doses of 5 and 10mg/kg did not signiﬁcantly
change NOx levels [56.58 ± 10.66 μM/g tissue (p= 0.88) and
51.84 ± 5.23 μM/g tissue (p=0.27), respectively].
4. Discussion
The results of the present experiment showed that acutely admini-
strated caﬀeine at doses of 5 and 50mg/kg had proconvulsant eﬀect,
while 100mg/kg of caﬀeine did not change the seizure threshold. When
administrated alone, 8-CPT (1 and 5mg/kg) had proconvulsant eﬀect,
while SCH-442416 (5 and 10mg/kg) or sildenaﬁl (5 and 10mg/kg) did
not change seizure threshold. On the other hand, pre-treatment with the
same doses of SCH-442416 or sildenaﬁl before 100mg/kg of caﬀeine
signiﬁcantly decreased seizure threshold, while proconvulsant eﬀect of
8-CPT (1 and 5mg/kg) disappeared in the presence of caﬀeine. Only
100mg/kg of caﬀeine signiﬁcantly decreased NOx levels. When ad-
ministrated alone, 8-CPT (1 and 5mg/kg) or SCH-442416 (5 and
10mg/kg) did not signiﬁcantly decrease NOx levels. In pre-treated
groups, only pre-treatment of 8-CPT (5mg/kg) before 100mg/kg of
caﬀeine signiﬁcantly decreased NOx levels.
Caﬀeine is the non-selective antagonist of ARs and its primary tar-
gets are A1Rs and A2ARs (Tchekalarova et al., 2010). Adenosine behaves
Fig. 4. Eﬀect of diﬀerent doses of sildenaﬁl (5 and 10mg/
kg, i.p.) alone and as pre-treatment before 100mg/kg of
caﬀeine on the PTZ-induced clonic seizure threshold;
***P < 0.001 in comparison with DMSO+Caﬀeine
group, ++P < 0.01 in comparison with 5mg/kg of sil-
denaﬁl alone group, ###P < 0.001 in comparison with
10mg/kg of sildenaﬁl alone group (mean ± SD, n=7).
Fig. 5. Eﬀect of diﬀerent doses of caﬀeine (5, 50, and 100mg/kg, i.p.) on NOx
levels in the brain; *P < 0.05 compared with the saline-treated control group
(mean ± SD, n=7).
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as an inhibitory neuromodulator in the brain and has anticonvulsant
action through activation of A1Rs (Dragunow, 1990). It seems that lo-
cally released adenosine has a crucial role in localizing epileptic focus
through activation of A1Rs (Fedele et al., 2006). In this context, A1Rs
knockout mice were more susceptible to seizures following experi-
mental traumatic brain injury (Kochanek et al., 2006). Nevertheless,
several pieces of evidence suggest caﬀeine as a proconvulsant agent
(Chu, 1981; De Sarro et al., 1997).
To explore the eﬀect of A1Rs, we examined the eﬀect of acute ad-
ministration of 8-CPT, a selective A1Rs antagonist, alone and as pre-
treatment before 100mg/kg of caﬀeine. Our results showed that low
concentrations of 8-CPT (2 and 5mg/kg, i.p.), when administered
alone, signiﬁcantly decreased seizure threshold. The declined seizure
threshold by the 8-CPT suggests proconvulsant eﬀect of A1Rs antago-
nists. Thus, proconvulsant eﬀect of 5 and 50mg/kg of caﬀeine in our
study was probably due to antagonizing eﬀect on A1Rs. Nevertheless, 8-
CPT did not alter the seizure threshold when administered before
100mg/kg of caﬀeine. Also, pre-treatment of 5mg/kg of 8-CPT before
100mg/kg caﬀeine resulted in a signiﬁcant increase of seizure
threshold compared to 5mg/kg of 8-CPT alone group. Diﬀerent eﬀects
of 8-CPT on seizure threshold in the absence and presence of caﬀeine
suggest the involvement of other signaling pathways such as the eﬀect
of caﬀeine on A2ARs or involvement of NO-cGMP pathway in the eﬀect
of caﬀeine on a seizure.
Results obtained from the administration of 100mg/kg of caﬀeine
conﬁrmed and extended previous results that some doses of caﬀeine
had no eﬀect against seizures. Our results are not the ﬁrst report re-
garding no eﬀect of caﬀeine against seizures. It has been previously
reported that acute administration of 60 or 80mg/kg of caﬀeine did not
signiﬁcantly change the PTZ-induced seizure threshold (Bankstahl
et al., 2012). In another study, acute administration of 46.2 and
92.4 mg/kg of caﬀeine showed no proconvulsant eﬀect in maximal
electroshock in mice (Jargiello-Baszak et al., 2016). Moreover, the
acute administration of caﬀeine (20mg/kg, P.O) did not change the
seizure threshold in juvenile and adult rats (Himmel, 2008). In contrast
to our results, caﬀeine at a dose of 92.4mg/kg signiﬁcantly reduced the
threshold for PTZ-induced clonic seizures in mice (Luszczki et al.,
2006). In another study, caﬀeine at doses of 150–200mg/kg produced
the clonic seizures in mice (Marangos et al., 1981).
The role of A2ARs in the modulation of seizure susceptibility has
been recently well established. Attenuation of PTZ-induced clonic sei-
zure in A2ARs knockout mice drinking water only was mimicked in
wild-type mice receiving caﬀeine in drinking water for 14 days (El
Yacoubi et al., 2008). In addition, A2ARs knockout mice were partially
resistant to limbic seizures (El Yacoubi et al., 2009). Considering these
ﬁndings, it is suggested that the eﬀect of acutely administrated 100mg/
kg of caﬀeine on seizure is not due to its antagonizing eﬀect on A2ARs.
Therefore, we used diﬀerent doses of SCH-442416 (5 and 10mg/kg)
before 100mg/kg of caﬀeine. When administered alone, SCH-442416
had no signiﬁcant eﬀect on PTZ-induced seizure threshold. Pre-treat-
ment with both doses of SCH-442416 before caﬀeine decreased PTZ-
induced seizure threshold. Since SCH-442416 is the selective antagonist
of A2ARs, it seems that the proconvulsant eﬀect of caﬀeine in the pre-
sence of SCH-442416 is partly due to its eﬀect on another signaling
pathway. Because SCH-442416 did not change seizure threshold per se
in our investigation, we concluded that the proconvulsant eﬀect of
caﬀeine is probably through antagonizing eﬀect on A1Rs.
Although caﬀeine can modulate seizure susceptibility mainly
through antagonizing eﬀect on ARs, other mechanisms may also be
involved in the central eﬀects of caﬀeine. In an unpublished work, we
have previously examined the involvement of the NO-cGMP pathway
using L-NAME or L-arginine in the central eﬀect of caﬀeine. Our results
Fig. 6. Eﬀect of diﬀerent doses of 8-CPT (1 and 5mg/kg, i.p.) alone and as pre-treatment before 100mg/kg of caﬀeine on NOx levels in the brain; *P < 0.05
comparison with DMSO+Caﬀeine group, ++P < 0.01 in comparison with 5mg/kg of the 8-CPT alone group (mean ± SD, n=7).
Fig. 7. Eﬀect of diﬀerent doses of SCH-442416 (5 and 10mg/kg, i.p.) alone and
as pre-treatment before 100mg/kg of caﬀeine on NOx levels in the brain
(mean ± SD, n=7).
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showed that L-arginine attenuated the eﬀect of 100mg/kg of caﬀeine
and had proconvulsant eﬀect. Since A2A receptor stimulation leads to
increase of NO production (Bruce et al., 2002), inhibitory eﬀect of
caﬀeine on A2ARs may lead to decrease of NO production. To further
investigate the role of the NO-cGMP pathway, we measured NOx levels
following acute administration of diﬀerent doses of caﬀeine. Based on
our results, 100mg/kg of caﬀeine signiﬁcantly decreased NOx levels in
the brain tissues. This dose of caﬀeine was the same dose that did not
change the seizure threshold. Thus, it is probable that the eﬀect of
100mg/kg of caﬀeine is partly due to a decrease in NO and attenuation
of the NO-cGMP pathway eﬀect on seizure activity. In this context,
proconvulsant eﬀect of 5mg/kg of 8-CPT disappeared and NOx levels
decreased in the presence of 100mg/kg of caﬀeine. This probably
points to the involvement of the NO-cGMP pathway in the eﬀect of
caﬀeine on seizure activity. As previously mentioned, the activation of
A2ARs results in an increase in the NO production (Bruce et al., 2002).
Thus, antagonizing the eﬀect of 100mg/kg of caﬀeine on A2ARs is likely
the main mechanism of the decrease in the NOx levels in the context of
the selective antagonizing eﬀect of 8-CPT. In comparison, 5 and 10mg/
kg of SCH-442416 showed proconvulsant eﬀect in the presence of
100mg/kg of caﬀeine without any signiﬁcant change in the NOx levels.
One possible mechanism is the eﬀect of caﬀeine on A1Rs without af-
fecting A2ARs in the presence of SCH-442416.
We also examined the eﬀect of pre-treatment with sildenaﬁl before
100mg/kg of caﬀeine on PTZ-induced seizure threshold. Pre-treatment
with sildenaﬁl resulted in proconvulsant eﬀect in the presence of
100mg/kg of caﬀeine. Sildenaﬁl is a selective PDE5 inhibitor that po-
tentiates the NO-mediated signaling pathway by preventing the cGMP
degradation (Kaster et al., 2005). Thus, it is obvious that the increase in
cGMP as a result of PDE5 inhibition is the main mechanism of pro-
convulsant eﬀect of pre-treatment with sildenaﬁl. Although caﬀeine per
se is a weak and non-selective inhibitor of PDEs at high doses, the eﬀect
of 100mg/kg of caﬀeine does not appear to be due to an elevation of
cGMP levels. Besides, results obtained from diﬀerent doses of sildenaﬁl
indicate that some eﬀect of 100mg/kg of caﬀeine may be due to in-
hibition of A2ARs and a subsequent decrease in NO production. One
explanation is that the decrease in NO and the resultant decrease in
cGMP are more important than the weak inhibitory eﬀect of caﬀeine on
PDE5. Moreover, it has been shown that several PDE inhibitors such as
theophylline inhibit sGC activity and decrease the level of cGMP
(Francis et al., 2011). However, there is no data regarding the in-
hibitory eﬀect of caﬀeine on sGC activity.
There are some limitations to our study. The Griess assay has been
utilized extensively as a reliable method to estimate the overall NO
production (Heinzen and Pollack, 2002). However, this method in-
directly measures total NOx, therefore non NO-related sources of NOx
may aﬀect the results. There are more precise methods for measuring
NO content, such as electron paramagnetic resonance (EPR) spectro-
scopy (kozlov et al., 1995). On the other hand, use of ARs knockout
mice instead of ARs antagonists could possibly exhibit more accurate
results.
5. Conclusions
In conclusion, we showed that acute administration of caﬀeine at
low doses (5 and 50mg/kg) had a proconvulsant eﬀect, while higher
dose of caﬀeine (100mg/kg) did not change the seizure threshold. The
eﬀect of 100mg/kg of caﬀeine on seizure threshold conﬁrmed and
extended the previous results showing that some doses of caﬀeine do
not change seizure threshold. Then, we demonstrated that the eﬀect of
caﬀeine is partly mediated through A1Rs and A2ARs receptors. Our re-
sults suggest that higher dose of caﬀeine probably has more inhibitory
eﬀect on A2ARs. This may explain why higher dose of caﬀeine increases
the seizure threshold with some doses of A1Rs antagonist. Finally, we
showed the involvement of the NO-cGMP pathway in the central eﬀect
of caﬀeine.
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